Retrospective Analysis of Pemetrexed-based Chemotherapy Regimens on Mid-elderly Non-Hodgkin's Lymphoma

Objective To analyze the safety and efficacy of pemetrexed-based chemotherapy on patients with mid-elderly non-Hodgkin's lymphoma.

Methods We retrospectively reviewed the clinical data of patients with non-Hodgkin's lymphoma treated with pemetrexed-based chemotherapy regimen from November 2016 to October 2018 in the Cancer Hospital of Chinese Academy of Medical Sciences, and systematically reviewed the relevant literatures.

Results We enrolled 10 patients with non-Hodgkin's lymphoma treated with pemetrexed-based chemotherapy: 7 cases of diffuse large B-cell lymphoma, 2 cases of angioimmunoblastic T cell lymphoma and one case of extranodal NK/T cell lymphoma. After tumor recurrence or progression, these patients were treated with pemetrexed-based chemotherapy. Four cases of diffuse large B-cell lymphoma reached partial remission and three cases progressed. The main adverse events were low grade myelosuppression and gastrointestinal reactions.

Conclusion Pemetrexed-based chemotherapy regimen may have certain effectiveness and safety on the patients with diffuse large B-cell lymphoma, especially primary central nervous system lymphoma.